ArticleEuropean radiology2026
Association between embolic agent choice and complications after transcatheter arterial embolization for colonic diverticular bleeding.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesAlthough various embolic agents are used for transcatheter arterial embolization (TAE) of colonic diverticular bleeding (CDB), comparative outcome data for different embolic agents are limited. We aimed to assess the association between embolic agent choice and early rebleeding and intestinal ischemia after TAE for CDB. MATERIALS AND
methodsWe conducted a nationwide retrospective cohort study using the Japanese Diagnosis Procedure Combination database between July 2010 and March 2022. Adults who underwent a first TAE for CDB with coils, gelatin sponge (GS) particles, or n‑butyl‑2‑cyanoacrylate (NBCA) were included. Multivariate logistic regression analyses were performed to evaluate the association of embolic agent choice with early rebleeding requiring intervention and intestinal ischemic complications, while adjusting for covariates and within-hospital clustering.
resultsThe cohort comprised 5625 patients (mean age 72 years ± 12 [standard deviation], 4020 men). Coils, GS particles, and NBCA were used in 59%, 30%, and 11%, respectively. The overall early incidence of rebleeding and intestinal ischemia was 12% and 1.0%, respectively. With coils as the reference, the adjusted odds ratio for GS particles was 1.38 (95% CI: 1.15-1.66; p = 0.001) for early rebleeding and 2.64 (95% CI: 1.43-4.90; p = 0.002) for intestinal ischemia, and those for NBCA were 0.69 (95% CI: 0.50-0.95; p = 0.03) for early rebleeding and 3.53 (95% CI: 1.72-7.22; p = 0.001) for intestinal ischemia.
conclusionsCompared with coils, GS particles were associated with an increase in both early rebleeding and intestinal ischemia, whereas NBCA was associated with decreased rebleeding and increased ischemia. KEY POINTS: Question Transcatheter arterial embolization (TAE) is one of the mainstay treatments for colonic diverticular bleeding, but outcome differences among embolic agents remain unclear. Findings Gelatin sponge particles increased both early rebleeding and intestinal ischemic risks, while coils reduced intestinal ischemic risk and n‑butyl‑2‑cyanoacrylate reduced early rebleeding risk. Clinical relevance Embolic material selection should be individualized for TAE in colonic diverticular bleeding. Coils may be safer in ischemia-prone patients, while n‑butyl‑2‑cyanoacrylate may be suitable for those at high risk of rebleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.